Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Letrozole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 known ✓ | P11511 | 20/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP11B1 | P15538 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | STS | P08842 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Letrozole SCHEMBL29079510 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL5326636 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL4331 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL1026263 | 0.98 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL28081077 | 0.98 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL19661207 | 0.92 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL5430341 | 0.92 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL13285157 | 0.92 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL10075551 | 0.92 | CYP19A1 (0.85) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| Letrozole SCHEMBL29046442 | 0.90 | CYP19A1 (0.81) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2278 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560959-B1 | ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-11-22 | — | — | EP | claimed |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | claimed |
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-12043667-B2 | CLEC12a binding polypeptides and uses thereof | INHIBRX BIOSCIENCES, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023178290-A9 | USE OF COMBINED CD274 COPY NUMBER CHANGES AND TMB TO PREDICT RESPONSE TO IMMUNOTHERAPIES | FOUNDATION MEDICINE, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240240147-A1 | CHIMERIC ANTIGEN RECEPTOR-MODIFIED GRANULOCYTE-MACROPHAGE PROGENITORS FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-07-18 | — | — | US | disclosed |
| EP-4399330-A1 | GENE FUSIONS IN SARCOMA | Foundation Medicine, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| US-12037385-B2 | Anti-polyubiquitin antibodies and methods of use | GENENTECH, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240228653-A1 | PSGL-1 Antagonists and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024148315-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2005001486-A1 | MODULATING THE INTERACTION BETWEEN HGF BETA CHAIN AND C-MET | GENENTECH, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2005000900-A1 | TREATMENT WITH ANTI-VEGF ANTIBODIES | GENENTECH, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004094476-A2 | COMPOSITIONS AND METHODS RELATING TO STOP-1 | GENENTECH, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1401476-A2 | IGF ANTAGONIST PEPTIDES | Genentech, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| EP-1330251-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-SENSITIVE DISEASE | Biomedicines, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030092631-A1 | IGF antagonist peptides | GENENTECH, INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072780-A2 | IGF ANTAGONIST PEPTIDES | GENENTECH, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020119502-A1 | Combination therapy for the treatment of estrogen-sensitive disease | INTARCIA THERAPEUTICS, INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002030429-A1 | COMBINATION THERAPY FOR THE TREATMENT OF ESTROGEN-SENSITIVE DISEASE | BIOMEDICINES, INC. (US) | 2002-04-18 | — | — | WO | disclosed |